February 27, 2026

COMPASS Pathways (CMPS) Stock Analysis: Unveiling a Potential 164.89% Upside in the Psychedelic Therapy Space

COMPASS Pathways Plc (NASDAQ: CMPS), a pioneering company in the development of innovative mental health therapies, is capturing the attention of investors with its promising product pipeline and significant upside..

Valneva SE (VALN) Stock Analysis: Potential Upside Amidst Challenging Metrics

Valneva SE (NASDAQ: VALN), a French biotechnology firm specializing in vaccines for infectious diseases, has garnered attention from investors, particularly due to its promising pipeline of prophylactic vaccines. Despite its..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: Unveiling a Potential 205% Upside in the Biotech Sector

Investors eyeing the biotechnology sector should take a close look at Niagen Bioscience, Inc. (NAGE), a company poised for substantial growth. With a market cap of $413.4 million, this U.S.-based..

Sonida Senior Living, Inc. (SNDA) Stock Analysis: Navigating Growth Amidst Challenges

Sonida Senior Living, Inc. (SNDA), operating within the healthcare sector as a key player in the medical care facilities industry, is currently under the spotlight for its recent financial performance..

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Unveiling a Potential 116% Upside in Healthcare Innovation

Organogenesis Holdings Inc. (NASDAQ: ORGO), a leading regenerative medicine company based in Canton, Massachusetts, presents a compelling narrative for investors with a keen interest in healthcare innovation. With a market..

Cel-Sci Corporation (CVM): Unpacking the 832% Upside Potential for This Biotech Innovator

Cel-Sci Corporation (NASDAQ: CVM), a clinical-stage biotechnology company based in Vienna, Virginia, is making waves in the healthcare sector with its groundbreaking approach to immunotherapy. Specializing in harnessing the immune..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Powerhouse with 76% Upside Potential

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company that has captured the attention of investors due to its promising pipeline in the healthcare sector’s biotechnology industry. With..

MBX Biosciences, Inc. (MBX) Stock Report: Analyzing a 74% Potential Upside in the Biotech Sector

MBX Biosciences, Inc. (NASDAQ: MBX), a promising player in the biotechnology sector, is capturing investor attention with its innovative approach to treating endocrine and metabolic disorders. With a market capitalization..

Cogent Biosciences, Inc. (COGT)

⚠️ No article content returned.

..

Castle Biosciences, Inc. (CSTL) Stock Analysis: Unveiling a Promising 50.96% Upside for Investors

Investors eyeing the healthcare sector may find Castle Biosciences, Inc. (NASDAQ: CSTL) an intriguing opportunity, particularly given its notable potential upside of 50.96%. With a focus on molecular diagnostics in..

Spyre Therapeutics, Inc. (SYRE): Investor Outlook Amid a 35% Potential Upside

Spyre Therapeutics, Inc. (NASDAQ: SYRE) stands as a compelling player in the biotechnology sector, primarily focused on developing innovative treatments for inflammatory bowel disease (IBD) and rheumatic diseases. With a..

KalVista Pharmaceuticals, Inc. (KALV): Investor Outlook with a Promising 115% Upside Potential

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presents an intriguing opportunity for investors looking to delve into the biotechnology sector, particularly within the realm of innovative therapies for diseases with unmet medical..

Enhabit, Inc. (EHAB) Stock Analysis: Navigating Challenges with Strategic Home Health and Hospice Services

Enhabit, Inc. (EHAB), a notable player in the U.S. healthcare sector, operates within the medical care facilities industry, primarily offering comprehensive home health and hospice services. Despite facing some financial..

Arvinas, Inc. (ARVN) Stock Analysis: Navigating the 6.50% Upside Potential Amidst Clinical Innovations

Arvinas, Inc. (NASDAQ: ARVN) stands as a pioneering player in the biotechnology sector, with a market capitalization of $982.33 million. Known for its cutting-edge work in the development of therapies..

Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 505% Potential Upside in the Biotech Sector

In the ever-evolving landscape of biotechnology, Upstream Bio, Inc. (NASDAQ: UPB) stands out as a promising player for investors eyeing the healthcare sector. With a focus on developing treatments for..

Verastem, Inc. (VSTM) Stock Analysis: Exploring a Potential 189% Upside in the Biotech Sector

Verastem, Inc. (NASDAQ: VSTM), a clinical-stage biopharmaceutical company, is captivating the attention of investors with a remarkable potential upside of 189.71%. This Massachusetts-based firm, specializing in oncology therapeutics, is developing..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating a Challenging Biotech Landscape with a 2.99% Potential Upside

Investors in the biotechnology sector are accustomed to navigating volatility, and Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is no exception. This Boston-based biotech innovator, with a market cap of $588.33..

GH Research PLC (GHRS) Stock Analysis: Exploring a Potential 115% Upside in the Biotech Arena

Investors on the lookout for high-growth opportunities in the biotechnology sector might find GH Research PLC (NASDAQ: GHRS) an intriguing prospect. Based in Dublin, Ireland, this clinical-stage biopharmaceutical company is..

EyePoint, Inc. (EYPT) Stock Analysis: Unpacking the 103% Potential Upside

EyePoint, Inc. (NASDAQ: EYPT) stands out in the biotechnology sector with a striking 103.43% potential upside, according to analyst ratings. This Massachusetts-based company is gaining traction with its cutting-edge therapeutics..

Altimmune, Inc. (ALT) Stock Analysis: Exploring a Potential 296% Upside in Biotech Investments

Altimmune, Inc. (NASDAQ: ALT) is a compelling prospect within the biotechnology sector, particularly for investors with an appetite for risk and a focus on high-reward opportunities. The company’s market capitalization..

Search

Funds

February 27, 2026

Search

Funds

February 27, 2026

FTSE 100

Funds